COR 003 - Novo Nordisk
Alternative Names: COR-003 - Novo Nordisk; D6PV; D6PV - Novo NordiskLatest Information Update: 28 Aug 2022
At a glance
- Originator Corvidia Therapeutics
- Developer Novo Nordisk
- Class Antihyperlipidaemics; Lipoproteins
- Mechanism of Action Apolipoprotein C stimulants; Apolipoprotein C-III modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hypertriglyceridaemia
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Hypertriglyceridaemia in USA
- 24 Jul 2018 Preclinical trials in Hypertriglyceridaemia in USA (unspecified route) (Corvidia Therapeutics pipeline July 2018)